5 results
Evaluation of the effect of daratumumab in combination with ATRA in patients with relapsed/refractory multiple myeloma
To evaluate the effectiveness and safety of concentration controlled combination of once daily dosed low-dose sirolimus (trough levels: 3-5 ng/ml) and extended-release tacrolimus (trough levels:3-5 ng/ml), in order to provide superior renal function…
The purpose of this study is to see if Daratumumab is useful for treating patients with relapsed or refractory Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), or Follicular Lymphoma (FL). Another purpose of the study is to see if…
Primary Objectives- To evaluate the pharmacokinetics and safety of the Dara-MD SC delivery of daratumumab (Part 1).- To evaluate the pharmacokinetics and safety of the Dara-CF SC delivery of daratumumab (Part 2).-To evaluate the safety of Dara-CF…
Primary* To evaluate safety and tolerability of LNP3794 at selected dose levelsSecondary* To determine the therapeutic relevant dose(s) of LNP3794* To describe the PK profile of LNP3794 following single and multiple oral administrationOther* To…